Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
First Published Online December 2, 2009
The Oncologist, Vol. 14, No. 12, 1198-1200, December 2009; doi:10.1634/theoncologist.2009-0165
© 2009 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
theoncologist.2009-0165v1
14/12/1198    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Michael, M.
Right arrow Articles by Melanthiou, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michael, M.
Right arrow Articles by Melanthiou, F.

The Community Oncologist: Case Reports

Development of Multiple Myeloma in a Patient with Chronic Myeloid Leukemia While on Treatment with Imatinib Mesylate for 65 Months

Michalis Michael, Marios Antoniades, Elena Lemesiou, Nicandros Papaminas, Freiderikh Melanthiou

Haematology Department of Nicosia General Hospital, Nicosia, Cyprus

Key Words. Chronic myeloid leukemia • Imatinib • Multiple myeloma • Immunomodulatory agents

Correspondence: Michalis Michael, M.D., Department of Haematology, Nicosia, General Hospital, 2 Amfipoleos Street, 2025, Nicosia, Cyprus. Telephone: 357-22603460; Fax: 357-22604348; e-mail: mixalis.mixail{at}gmail.com

Received July 26, 2009; accepted for publication November 17, 2009; first published online in THE ONCOLOGIST Express on December 2, 2009.

Disclosures: Michalis Michael: None; Marios Antoniades: None; Elena Lemesiou: None; Nicandros Papaminas: None; Freiderikh Melanthiou: None.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent peer reviewers.

The simultaneous occurrence of multiple myeloma (MM) and chronic myeloid leukemia (CML) is an extremely rare event that has been reported in only eight cases in the literature. We report here on only the third case of the development of MM in a patient with CML on treatment with imatinib mesylate, and to our knowledge, this is the first case in a patient who received imatinib as first-line treatment.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2009 by AlphaMed Press.
Advertisement